Navigation Links
Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol
Date:8/31/2017

A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.

The Phase 2 study, newly underway at Providence Cancer Center, is led by Kristina Young, M.D., Ph.D., who was recognized in 2016 as one of 15 most promising young researchers in the nation by the Sidney Kimmel Foundation for Cancer Research.

The trial is open to patients with Stage 2 and higher rectal cancer who are slated to undergo the standard treatment of radiation and chemotherapy prior to surgery. The clinical trial adds an additional component to the pre-surgery radiation/chemotherapy regimen – immunotherapy. It is administered in the form of daily pills for two weeks prior to radiation and chemotherapy, and then during that treatment as well.

Radiation and chemotherapy treatments are given prior to surgery with the hope they will shrink the tumor slightly. Dr. Young’s pre-clinical research suggests adding the immunotherapy protocol will increase shrinkage of the tumor. Young is working with Galunisertib, a drug under development by Eli Lilly and Company. She describes the drug as helping the body rev up the immune system to fight the cancer.

The first three patients to participate in the clinical trial have shown a “dramatic response,” according to Dr. Young. One patient’s tumor completely disappeared, while the two other patients had more than a 75 percent decrease in tumor size, with equally impressive responses in the lymph nodes.

“These initial responses are very exciting and make us hopeful that this therapy will improve outcomes for this deadly disease,” said Dr. Young.

The Phase 2 clinical trial will enroll 50 patients. If the tumors of at least 18 patients disappear, that would more than double the typical response of chemotherapy and radiation, and would be seen as contributing to the success of the trial.

This trial is a continuation of Dr. Young’s post-doctoral work on modifying the tumor microenvironment in combination with radiation to improve the outcome for patients with rectal cancer. When Dr. Young was honored with the Kimmel Scholar Award last year, the recognition came with a two-year, $200,000 grant to further her work on harnessing the patient’s own immune system to eradicate cancer. The funding allowed her to further investigate each patient’s immune response to their tumor while enrolled in this trial. This particular type of immunotherapy has great potential for use across many tumor types. “We are working on writing clinical trials in breast and head and neck cancer, which have shown promising results in the lab,” said Dr. Young.

Learn more about the clinical trial here or call 503-215-2614.

Dr. Young is a radiation oncologist with The Oregon Clinic and an Assistant Member at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14644140.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Pharmalto Named One of the “20 Most Promising Healthcare Solution Providers 2017” by CIOReview Magazine
2. United States Surgeon General, Dr. Vivek Murthy, Shares what Fuels his Uncompromising Commitment to a Healthier Nation in Mediaplanet’s “Careers in Health Care” Campaign
3. Compliancy Group Named One of Healthcare Tech Outlook's 10 Most Promising Healthcare Compliance Solution Providers 2016
4. CloudLIMS named in 20 Most Promising Pharma and Life Sciences Tech Solution Providers 2016 by CIOReview
5. DataPoint Named on List of 20 Most Promising SharePoint Solution Providers
6. Personalized Learning Study’s “Promising” Claims Diminished by Limited Evidence and Weak Generalizability, Says New NEPC Review
7. The Center for Advancing Innovation and The Medical Center of the Americas Partner to Launch the SPACE RACE to Advance Promising NASA Inventions
8. Mesothelioma Experts Focus on Promising Immunotherapy Drug in New Article, According to Surviving Mesothelioma
9. CIOReview Selects Smartlink Mobile Systems for 50 Most Promising Healthcare Solution Providers 2015
10. Promising New Antimicrobials Could Fight Drug-Resistant MRSA Infection, New Georgia State Study Finds
11. Newly-Published Review of Promising Mesothelioma Drug Finds Value Questions Remain, According to Surviving Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
(Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Bill Howe Plumbing’s ... its customers, and give back to the community. For over 37 years, they have ... successful companies serving plumbing in San Diego. They were chosen as the ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum ... at the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, ... ensuring label quality and improving patient safety. , Microscan , a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... and highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge ... survival rates. , Preora has been named a Top 100 Finalist ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology: